- Diabetes, obesity and metabolism
- Effectiveness of a Social Networking Site Based Automatic Mobile Message Providing System on Glycemic Control in Patients with Type 2 Diabetes Mellitus
-
Kyuho Kim, Jae-Seung Yun, Joonyub Lee, Yeoree Yang, Minhan Lee, Yu-Bae Ahn, Jae Hyoung Cho, Seung-Hyun Ko
-
Endocrinol Metab. 2024;39(2):344-352. Published online December 27, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1871
-
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
This study investigated the effectiveness of a social networking site (SNS)-based automatic mobile message providing system on glycemic control in patients with type 2 diabetes mellitus (T2DM).
Methods
A 3-month, randomized, open-label, controlled, parallel-group trial was conducted. One hundred and ten participants with T2DM were randomized to a mobile message system (MMS) (n=55) or control group (n=55). The MMS group received protocolbased automated messages two times per day for 10 weeks regarding diabetes self-management through KakaoTalk SNS messenger. The primary outcome was the difference in the change in glycated hemoglobin (HbA1c) levels (%) from baseline to week 12.
Results
HbA1c levels were more markedly decreased in the MMS group (8.4%±0.7% to 8.0%±1.1%) than in the control group (8.5%±0.8% to 8.4%±0.8%), resulting in a significant between-group difference (P=0.027). No differences were observed in changes in fasting glucose levels, lipid profiles, and the number of participants who experienced hypoglycemia, or in changes in lifestyle behavior between groups. However, the self-monitoring of blood glucose frequency was significantly increased in the MMS group compared to the control group (P=0.003). In addition, sleep duration was increased in the MMS group, but was not changed in the control group.
Conclusion
An SNS-based automatic mobile message providing system was effective in improving glycemic control in patients in T2DM. Studies which based on a more individualized protocol, and investigate longer beneficial effect and sustainability will be required in the future.
- Diabetes, Obesity and Metabolism
- Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
-
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
-
Endocrinol Metab. 2022;37(4):575-586. Published online August 29, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.402
-
-
12,616
View
-
563
Download
-
19
Web of Science
-
21
Crossref
-
Abstract
PDFPubReader ePub
- High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)–lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.
-
Citations
Citations to this article as recorded by  - The chylomicron saga: time to focus on postprandial metabolism
Alejandro Gugliucci
Frontiers in Endocrinology.2024;[Epub] CrossRef - Sanghuangporus vaninii extract ameliorates hyperlipidemia in rats by mechanisms identified with transcriptome analysis
Ning Gao, Yuanzhen Liu, Guangjie Liu, Bo Liu, Yupeng Cheng
Food Science & Nutrition.2024; 12(5): 3360. CrossRef - Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Monika I. Konaklieva, Balbina J. Plotkin
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef - Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave Dixon, Terry A. Jacobson
Obesity Pillars.2024; 10: 100108. CrossRef - Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
Diabetes & Metabolism Journal.2024; 48(2): 184. CrossRef - Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models
Wan-Yun Gao, Pei-Yi Chen, Hao-Jen Hsu, Je-Wen Liou, Chia-Ling Wu, Ming-Jiuan Wu, Jui-Hung Yen
Biomedicine & Pharmacotherapy.2024; 174: 116598. CrossRef - Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
Harold Edward Bays, Carol F. Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave L. Dixon, Terry A. Jacobson
Journal of Clinical Lipidology.2024; 18(3): e320. CrossRef - Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study
Ming‐Ling Chang, Jennifer Tai, Jur‐Shan Cheng, Wei‐Ting Chen, Sien‐Sing Yang, Cheng‐Hsun Chiu, Rong‐Nan Chien
Diabetes, Obesity and Metabolism.2024; 26(7): 2969. CrossRef - Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study
Wang Zhao, Yangang Wang, Jin Li, Tao Chen, Delu Yin, Hailong Dai, Zhuhua Yao, Shuiping Zhao
Lipids.2024; 59(5): 145. CrossRef - Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Rui Shang, Brian Rodrigues
Journal of Pharmacy & Pharmaceutical Sciences.2024;[Epub] CrossRef - The Relationship Between Remnant Cholesterol and Visceral Adipose
Tissue: A National Cross-Sectional Study
Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang
Hormone and Metabolic Research.2024;[Epub] CrossRef - Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions
Mili Shah, Abisheikh Sharma, Mohammed Ayyad, Ethan Swartz, Danyaal Jafrani, Dhir Gala
Cureus.2024;[Epub] CrossRef - Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies
Alejandro Gugliucci
Journal of Clinical Medicine.2024; 13(17): 5229. CrossRef - High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis
Franziska Schmalz, Janett Fischer, Hamish Innes, Stephan Buch, Christine Möller, Madlen Matz-Soja, Witigo von Schönfels, Benjamin Krämer, Bettina Langhans, Alexandra Klüners, Michael Soyka, Felix Stickel, Jacob Nattermann, Christian P. Strassburg, Thomas
JHEP Reports.2023; 5(4): 100684. CrossRef - Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
Dieter Lütjohann, Hans-Ulrich Klör, Frans Stellaard
Nutrients.2023; 15(9): 2202. CrossRef - Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
Tien-Yuan Wu, Ni Tien, Cheng-Li Lin, Yu-Cun Cheah, Chung Y. Hsu, Fuu-Jen Tsai, Yi-Jen Fang, Yun-Ping Lim
Frontiers in Medicine.2023;[Epub] CrossRef - Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Alejandro Gugliucci
Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef - Sugar and Dyslipidemia: A Double-Hit, Perfect Storm
Alejandro Gugliucci
Journal of Clinical Medicine.2023; 12(17): 5660. CrossRef - Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Sang Heon Suh, Soo Wan Kim
Diabetes & Metabolism Journal.2023; 47(5): 612. CrossRef - Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
Biomedicines.2023; 11(10): 2696. CrossRef - Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study
Julia Hernandez-Baixauli, Gertruda Chomiciute, Juan María Alcaide-Hidalgo, Anna Crescenti, Laura Baselga-Escudero, Hector Palacios-Jordan, Elisabet Foguet-Romero, Anna Pedret, Rosa M. Valls, Rosa Solà, Miquel Mulero, Josep M. Del Bas
Scientific Reports.2023;[Epub] CrossRef
|
KES
